SEATTLE, April 09, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global anti-epileptic drugs market is estimated to be valued at US$ 7,155.6 million in 2019, and is expected to exhibit a CAGR of 6.6% over the forecast period (2019-2027).
Key Trends and Analysis of the Global Anti-epileptic Drugs Market:
The global anti-epileptic drug market is expected to generate high revenue over the forecast period, owing to increasing regulatory approval of epilepsy drugs. For instance, in 2016, UCB Pharma Limited received the U.S. FDA approval for its Briviact, for the treatment of patients with partial onset seizures. Moreover, Mylan launched generic, Felbatol tablets, in the U.S. after receiving approval from the U.S. Food & Drug Administration in 2016. These factors are expected to boost the market growth over the forecast period.
Furthermore, in December 2018, GlaxoSmithKline plc received approval of its Lamictal dispersible tablet by the National Medical Products Administration China (NMPA), for launch, and for the treatment of various seizure types and Lennox-Gastaut syndrome (LGS) in adults and children with epilepsy.
Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/1701
Moreover, key players in the market are focused on collaborations and partnerships, in order to commercialize epilepsy drugs and gain competitive edge in the global market. For instance, in 2014, UCB Pharma entered into an agreement with Daiichi Sankyo Company, Limited to commercialize Lacosamide for epilepsy patients in Japan. Under this agreement, UCB will manufacture and supply the product for commercialization.
In addition, key players are focusing on development of epilepsy drugs and this is expected to boost the market growth over the forecast period. For instance, in February 2019, SK Biopharmaceuticals and Arvelle Therapeutics signed an agreement to develop and commercialize SK Biopharmaceuticals' cenobamate in Europe. Cenobamate is anti-epileptic drug indicated for the treatment of partial-onset of seizures in adults.
Key Market Takeaways:
- The global anti-epileptic drug market is expected to exhibit a CAGR of 6.6% over the forecast period (2019-2027), owing to increasing launches of drugs. For instance, in February 2019, Teva Pharmaceutical Industries Ltd. launched generic version of Sabril (vigabatrin) tablets in the U.S. Sabril (vigabatrin) is indicated as adjunctive therapy for adults and children (10 years of age or older) with refractory complex partial seizures (CPS).
- Among regions, North America is expected to hold a dominant position in the global anti-epileptic drug market over the forecast period, owing to increasing number of product approvals by regulatory authorities in the region. For instance, in November 2019, SK Life Science, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its XCOPRI (cenobamate tablets), indicated for the treatment of partial-onset seizures in adults.
Major players operating in the global anti-epileptic drug market include—
Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., Bausch Health Companies Inc., and UCB S.A.
Buy this Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/1701
Market Segmentation:
- Global Anti-epileptic Drugs Market, by Generation:
- First Generation
- Second Generation
- Third Generation
- Global Anti-epileptic Drugs Market, by Route of Administration:
- Oral
- Intravenous
- Global Anti-epileptic Drugs Market, by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Anti-epileptic Drugs Market, by Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Did not find what you were looking for? Here are some similar Topics:
HYDROXYCHLOROQUINE MARKET
The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to evaluate the efficacy of hydroxchloroquine tablets for the treatment of patients with coronavirus disease (COVID 19) are expected to propel the market growth over the forecast period.
Read more @ https://www.coherentmarketinsights.com/market-insight/hydroxychloroquine-market-3727
ANTI-MALARIA DRUGS MARKET
Malaria is considered as a life-threatening disease affecting large number of population across the world. According to the World Health Organization (WHO), in 2018, around 228 million estimated cases of malaria were diagnosed, globally. Moreover, global death toll due to malaria reached 405,000 in 2018 and an estimated 219 million cases were diagnosed in 2017.
Read more @ https://www.coherentmarketinsights.com/market-insight/anti-malarial-drugs-market-3726